Introduction
The organic anion transporting polypeptides OATPs are key membrane bound transporters expressed in many organs including intestine, liver, lung, choroid plexus, blood brain barrier and other organs (Tamai et al., 2000) . This transporter family mediates sodiumindependent transport of a diverse array of molecules that are mostly anions as well as organic cations, steroid conjugates, organic anions and xenobiotics (Bossuyt et al., 1996; Hagenbuch and Meier, 2004) by coupling uptake with the efflux of bicarbonate (Satlin et al., 1997) or glutathione (Li et al., 1998) . The OATPs share some substrate overlapping specificity with other promiscuous efflux transporters such as P-gp and MRP2, indicative of a degree of coordination. As a result, OATPs have been implicated in drug-drug interactions (Kim, 2003) , as exemplified by the interactions between cerivastatin and cyclosporine A (Shitara et al., 2003) as well as cerivastatin, gemfibrozil and its glucuronide metabolite .
Thirty six mammalian OATPs have been identified, but only a few of these have been characterized in any detail. Currently, 11 human OATPs have been identified and a new species independent nomenclature system has been proposed for all of the OATPs (SLCO) . OATP1B1 (previous names OATP-C, LST-1, OATP2, SLC21A6), consisting of 670 amino acids with 12 putative membrane spanning domains, represents the most studied human OATP to date (Meier and Stieger, 2000) , and is expressed on the basolateral plasma membrane of hepatocytes. This transporter has been well characterized when transfected in Xenopus laevis oocyte and other expression systems such as CHO, HeLa and Hek-293 cells. Many diverse molecules with a range of K m values are substrates of this protein, including pravastatin, dehydroepiandrosterone sulfate (DHEAS) and bromosulfophthalein (BSP) ( Table 1) .
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5 An equally well studied rat SLCO namely, Oatp1a1 (Oatp1, Oatp, Slc21a1) that is expressed in the liver, kidney and choroid plexus appears to share many of the same substrates as OATP1B1 (67% identity) as well as organic cations (Table 2 ). The considerable substrate overlap of these rat and human transporters, though by no means identical (Meier et al., 1997) , could suggest some degree of structural homology in key substrate recognition areas of the proteins that may require assessment using site-directed mutagenesis or other methods. As no high-resolution structures are presently available for these transporters, it is necessary to gain structural insight from alternative methods. If sufficient binding data are generated in vitro, these can be used to build a three-dimensional quantitative structure activity relationship (3D-QSAR) models (Ekins and Swaan, 2004) . A recent report has briefly discussed 3D-QSAR studies of Oatp/OATP substrates which apparently produced a pharmacophore containing 2 hydrogen bond acceptors, one hydrogen bond donor and two hydrophobic regions, although no model was shown or further details provided . It is likely that computational modeling techniques can provide structural insights into the molecular features of substrates that are common to these OATP transporters; alternatively, they may indicate those structural features that differentiates one OATP from the other. In the present study, we generated pharmacophore models for rat Oatp1a1 and human OATP1B1 with published K m values from different experimental systems. Metaanalysis of the individual models allowed us to provide an understanding of the key molecular features for substrate-OATP transporter interactions.
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Methods
Literature search. A complete literature search was performed up to September 2004 to retrieve substrates for each OATP evaluated in this study. Various databases were consulted for this task including PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi), the TP-search transporter database (http://www.ilab.rise.waseda.ac.jp/tp-search/) and ISI Web of knowledge (http://isiwebofknowledge.com/). Details from the publications were noted such as the cell system used for transfection, the K m value, and the species. Considerable care was taken to assign molecules to the correct OATP/Oatp. Comparisons between substrates with K m data shared between Oatp1a1 and OATP1B1 were used to derive a correlation (Table 3) .
In cases where multiple values for the same substrate could be found for each cell line, the mean value was then computed.
OATP pharmacophore development with Catalyst™. The computational molecular modeling studies were carried out using a Silicon Graphics (Palo Alto, CA) Octane workstation. Briefly, models were constructed using Catalyst™ version 4.9 (Accelrys, San Diego, CA) to generate hypotheses. Molecules for each OATP were initially sketched in ChemDraw version 7.0.1 (CambridgeSoft, Cambridge, MA), saved in mol file format, and then imported into Catalyst™. The 3-D molecular structures were produced using up to 255 conformers with the fast conformer generation method, allowing a maximum energy difference of 20 kcal/mol. Ten hypotheses were generated using these conformers for each of the molecules in the training sets and the K m values, after selection of the following features:
hydrophobic, hydrogen bond acceptor, hydrogen bond donor, and the positive and negative ionizable features for the substrates in the algorithm within Catalyst™. After assessing all 10 JPET #82370 7 hypotheses generated, the lowest energy cost hypothesis was considered the best as this possessed features representative of all the hypotheses and had the lowest total cost.
The quality of the structure activity correlation between the estimated and observed activity values was estimated by means of an r value. Statistical significance of the retrieved hypothesis was verified by permuting (randomizing) the response variable ten times, i.e. the activities and structures of the training set compounds were mixed ten times (so that each value was no longer assigned to the original molecule) and the Catalyst™ hypothesis generation procedure was repeated. The total energy cost of the generated pharmacophores can be calculated from the deviation between the estimated activity and the observed activity, combined with the complexity of the hypothesis (i.e. the number of pharmacophore features).
A null hypothesis can also be calculated which presumes that there is no relationship in the data and the experimental activities are normally distributed about their mean. Hence, the greater the difference between the energy cost of the generated hypothesis and the energy cost of the null hypothesis, the less likely it is that the hypothesis reflects a chance correlation.
Validation of the Catalyst Models. The test sets contained molecules not included in the initial training sets as described previously. These test set molecules were fit by the fast-fit algorithm to the respective Catalyst™ models in order to predict a value as previously described for CYPs (Ekins et al., 1999) . Fast fit refers to the method of finding the optimum fit of the substrate to the hypothesis among all the conformers of the molecule without performing an energy minimization on the conformers of the molecule.
Merging Catalyst Models. Pharmacophore models generated for different cell types for each transporter were merged in Catalyst using a pairwise comparison. Final pharmacophore models with the inter-feature distances labeled for clarity were illustrated JPET #82370 8 using MOLEKEL 4.3, (Swiss Center for Scientific Computing, Manno, Switzerland) (Portmann and Luthi, 2000) .
Statistical evaluation of test set predictions.
Observed and predicted data were graphed and fit using KaleidaGraph (Synergy Software, Reading, PA) to generate an r (correlation) value. The non parametric Spearman Rho values were calculated as a measure of rank ordering in the test data using JMP version 5.1 (SAS institute Inc, Cary, NC), where a value of 1 is optimal.
Results

Correlation between substrate data for rat Oatp1a1 and human OATP1B1
Overlapping substrate affinity for OATPs has been previously suggested due to the relatively close phylogenetic proximity of members of the OATP family. We have therefore made several comparisons using literature data published by many groups. Comparisons between substrates with K m data shared between rat Oatp1a1 and human OATP1B1 (Table 3) were used to derive a correlation (logK m, oatp1a1 =0.55logK m, OATP1B1 + 0.68). The analysis of all published data available to date across both of these transporters suggests 8 molecules in common which provides a reasonable correlation for the K m values (r 2 of 0.64).
Pharmacophores for human OATP1B1
Using the substrates described in the literature (Table 1) , sufficient data were available from Hek-293 cells and Xenopus laevis oocytes expressing OATP1B1 to generate two separate pharmacophores. The OATP1B1-oocyte data set consisted of 12 molecules (K m range 0.0076 -17 µM) in the training set. The pharmacophore generated in Catalyst contained 2 hydrogen bond acceptors and three hydrophobes ( Figure 1A ) with an observed versus predicted correlation (r = 0.97) but minimal difference between the null and total cost values (Supplemental Table 1 ). Similarly, after scrambling the molecules and K m data, insignificant difference was found in the statistics. A second pharmacophore, OATP1B1-Hek consisted of 12 molecules (K m range 0.1 -268 µM) in the training set. The pharmacophore generated in Catalyst contained 2 hydrogen bond acceptors and one hydrophobe ( Figure 1B) with an observed versus predicted correlation (r = 0.91) but minimal difference between the null and total cost values. However after scrambling the molecules and K m data the correlation decreased. Both pharmacophores compared favorably when merged, with good overlap of the hydrogen bond acceptor features and central hydrophobic features ( Figure 1C ).
Pharmacophores for rat Oatp1a1
Among the data available on substrates described in the literature on oocytes, CHO and HeLa cells expressing Oatp1a1 (Table 2) , it was apparent that 3 separate pharmacophores could be generated. The Oatp1a1-oocyte data set consisted of 14 molecules (K m range 0.015 -3300 µM) in the training set (s-dinitrophenyl-glutathione was excluded as it was an outlier).
The pharmacophore generated in Catalyst contained 2 hydrogen bond acceptors and three hydrophobes ( Figure 1D ), with an observed versus predicted correlation (r = 0.92; Figure 2) and a thirty points difference between the null and total cost values (Supplemental Table 1 ).
Similarly, a decrease in correlation and increase in the total cost were found after scrambling the molecules and K m data. A second pharmacophore, Oatp1a1-CHO consisted of 12 molecules (K m range 3 -3000 µM) in the training set. The pharmacophore generated in Catalyst contained 1 hydrogen bond acceptor and two hydrophobes ( Figure 1E ), with an observed versus predicted correlation (r = 0.90) but minimal difference between the null and total cost values. However, the correlation was found to decrease with no change in the total cost upon scrambling the molecules and K m data. A third pharmacophore, Oatp1a1-HeLa, consisted of 9 molecules (K m range 3.1 -214 µM) in the training set. The pharmacophore generated in Catalyst contained 1 hydrogen bond acceptor, one hydrophobe and one negative ionizable feature ( Figure 1F ) with an observed versus predicted correlation (r = 0.95) and larger total than null cost value. However, no change was found after scrambling the molecules and K m data. The three pharmacophores compared favorably when merged, with good overlap of the hydrogen bond acceptor features and central hydrophobic feature, while
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11 the negative ionizable feature was only present in one of three models which was generated with a narrower K m range ( Figure 1G ).
Meta pharmacophores for rat Oatp1a1 and human OATP1B1
Due to the limited size of the training sets generated for each model with individual cell types, we attempted to increase the training set scope by combining data from multiple cell types. Combining data for the rat Oatp1a1 resulted in a training-set of 26 molecules (K m range 0.015 -3300 µM). The meta-pharmacophore generated in Catalyst contained 2 hydrogen bond acceptors and three hydrophobes ( Figure 1H ) with a good observed versus predicted correlation (r = 0.90) and over a 30 point difference between the null and total cost values (Supplemental Table 1 ). After scrambling the molecules and K m data the correlation decreased and the total cost increased to close to the null value. Combining data for the human OATP1B1 resulted in a training set of 18 molecules (K m range 0.0076 -268 µM). The meta-pharmacophore generated in Catalyst contained 2 hydrogen bond acceptors and three hydrophobes ( Figure 1I ) with an observed versus predicted correlation (r = 0.92) and nearly a 20-point difference between the null and total cost values (Supplemental Table 1 ). After scrambling the molecules and K m data the correlation decreased and the total cost increased.
Conformational features of the meta-pharmacophores.
The molecules BSP, cholate, DHEAS, estrone-3-sulfate and taurocholate exist in the training sets for meta-OATP1B1and meta-Oatp1a1. To illustrate that these molecules would map to the meta-pharmacophores, their relative positioning is shown in Figure 3 . DHEAS shows medium affinity to Oatp1a1, and low affinity to OATP1B1 This is validated in our OATP1B1 meta-pharmacophore models because the molecule fails to occupy a hydrophobic feature and hydrogen bond acceptor ( Figure 3A, C) . DHEAS fits reasonably well to all Oatp1a1 pharmacophore features as expected from its relatively high affinity to Oatp1a1
( Figure 3B ). The relative molecular dimensions of the pharmacophoric feature points is illustrated in Fig 3D-F . It should be noted that the OATP1B1 pharmacophore that includes bilirubin occupies twice the dimensions of the oatp1a1 and OATP1B1 (without bilirubin) models.
External test sets for human OATP1B1 and rat Oatp1a1 pharmacophores
Additional molecules not included in the individual training sets for each cell type 
External Test Set Validation
We have previously shown (Pang et al., 1998 ) that BSP-GSH is transported by rat Oatp1a1, while enalaprilat, hippuric acid, benzoic acid, and harmol sulfate were not. These molecules form an excellent external test for our Oatp1a1 pharmacophore model. Hippuric acid and benzoic acid failed to fit to the model (indicative of them not being substrates) and enalaprilat, and harmol sulfate resulted in modest to high K m values (69 µM and 550 µM respectively). BSP-GSH, the glutathione adduct of BSP, was predicted to have a K m value of 23 µM, which indicates it is a good substrate, further validating the Oatp1a1-meta pharmacophore model. Recently, troglitazone, its metabolites and similar compounds were shown to produce statistically significant inhibition of estrone-3-sulfate uptake in OATP1B1 JPET #82370
13 (Nozawa et al., 2004) . Indeed, when these molecules are fitted to the OATP1B1 meta model (without bilirubin) they are all predicted to have affinity for this transporter: troglitazone (predicted K m 7.9 µM), troglitazone glucuronide-M2 (1.6 µM), troglitazone sulfate-M1 (5.6 µM), troglitazone quinone-M3 (6.7 µM), pioglitazone (14 µM), and rosiglitazone (9.9 µM).
The OATP1B1 inhibitor indocyanine green (Cui et al., 2001 ) was also fitted to this same pharmacophore showing an overlap to the two hydrophobes and one hydrogen bond acceptor (predicted K m 6.3 µM).
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Discussion
In the absence of crystal structures for many of the membrane bound proteins involved in interactions with xenobiotics and endobiotics such as enzymes and transporters, computational approaches have been extremely useful in gaining insight into the ligandprotein interaction(s). However, the quality and consistency of datasets have been a determining factor in the overall predictive value of the QSAR models to date. It has been particularly challenging to assimilate and model data acquired across species and experimental cell systems. As a result, most QSAR studies have focused on datasets gathered from one species, cell type, and frequently, one laboratory setting. In the present study we aimed to overcome these issues by a combination of pharmacophore building and metaanalysis.
To our knowledge the application of QSAR models for OATP or Oatp has been limited largely due to the absence of consistent datasets. A notable exception is a recent study by Yarim and co-workers on rat oatp1a5 (Yarim et al., 2005) who used CoMFA on 18
substrates. An improved understanding of the structural requirements of the OATPs may explain the mechanisms underlying the reported drug-drug interactions as due to transporter inhibition (Kim, 2003) . As some studies have described multiple inhibitors of uptake with EC 50 values (Tirona et al., 2003) , it may be possible to generate similar pharmacophores for inhibitors of the respective transporter. However, the difficulty in interpretation of whether these molecules are interacting with the same site or even sites responsible for transport is a disadvantage compared to modeling substrate K m data. It is therefore important to determine the critical features of OATP substrates, in particular the extensively studied rat Oatp1a1 and human OATP1B1.
Using the spectrum of substrates collated from the literature (Table 1) , we built 2 pharmacophores with Hek-293 cells and X. laevis oocytes expressing OATP1B1 ( Figure   1A ,B). Both pharmacophores had high correlations and contained multiple hydrogen bond acceptors and hydrophobic features which overlapped when merged, suggesting overlap ( Figure 1F ). Small differences between the null and total cost values (Supplemental Table 1 , online) before and after scrambling the molecules and K m data indicated these models may be limited. Ideally upon scrambling one would expect the training set correlation to diminish as the affinity data is randomly assigned with molecular structure and the total cost for the hypothesis will be similar to the null hypothesis cost. This simple test can give some idea of whether the model derived originally is meaningful or likely to be similar to one generated with random data. Literature data for the Oatp1a1 substrates (Table 2 ) yielded 3 pharmacophores ( Figure 1C-E) . Interestingly, all models were subtly different but shared hydrogen bond acceptors and hydrophobes, resulting in good overlaps in the merged pharmacophore. One Oatp1a1 pharmacophore contained a negative ionizable feature that likely relates to the most active molecules in the training set. Most of these models showed decreases in the training correlation and increases in the total cost after scrambling, indicating these models are of some utility. It is important to note that relatively small literature training sets (i.e. <20 compounds) can dramatically impact the model cost statistics and their behavior upon scrambling.
Test sets were generated from the molecules not initially included in the individual cell type pharmacophores, but results were variable due to the limited nature of the test sets.
By combining data from different cell types we increased the training set scope for each transporter model both in terms of the number of molecules and the activity range. These so-
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16 called meta-pharmacophores for rat Oatp1a1 and human OATP1B1 both contained 2 hydrogen bond acceptors and three hydrophobes ( Figure 1G -I) although with different 3D
coordinates (Supplemental Table 2 ). Both models had larger differences between null and total cost values with similar observed versus predicted correlations compared with the individual models generated with separate cell lines. Also, after scrambling the molecules and K m data for these meta-pharmacophores, the correlations decreased and the total cost increased for both models, indicating that they are statistically significant. It seems therefore, that the degree of correlation between substrates for these two transporters observed earlier could, in part, be due to the possession of similar molecular features necessary for interaction with each transporter, while the exact 3D coordinates differ to some extent. The key pharmacophore features for both of these transporters appear to be two hydrogen bond acceptors at either end of a large hydrophobic area. These features will correspond with hydrogen bond donors and a large planar hydrophobic recognition site on the respective transporters.
Five molecules (BSP, cholate, DHEAS, estrone-3-sulfate and taurocholate) exist in both training sets for meta-OATP1B1and meta-Oatp1a1. All but DHEAS have similar relative affinity to both transporters and map to both pharmacophores . The fact that DHEAS shows medium affinity to Oatp1a1, and low affinity to OATP1B1 makes it a good substrate to compare both pharmacophore models. Hence, DHEAS was fitted to both pharmacophore models (Figure 3) . A hydrophobic feature and hydrogen bond acceptor was missed and explained the low affinity of DHEAS to OATP1B1 ( Figure 3A) . DHEAS fits reasonably well to all Oatp1a1 pharmacophore features and correlates with its relatively high affinity to Oatp1a1 ( Figure 3B ). Our models could, therefore, successfully distinguish the affinity of DHEAS.
There is some controversy in the literature as to whether unbound bilirubin is a substrate for OATP1B1 and its inclusion in the meta-pharmacophore may necessitate further evaluation. Although it was shown to be a substrate in both Hek-293 cells and oocytes (Table   1) , no transport was observed in HeLa and Hek-293 cells by Wang and colleagues . We have therefore generated a meta-pharmacophore without bilirubin and found that this pharmacophore no longer has three hydrophobic features and has less optimal training set statistics due to the narrowing of the K m range. The mapping of DHEAS to this modified meta-model is consistent with the initial model as it maps to both hydrophobic features and one hydrogen bond acceptor feature ( Figure 3C ), suggesting that the hydrophobic feature removed after exclusion of bilirubin is not critical to the overall model. Our data are unlikely to end the controversy over whether or not bilirubin is a substrate for OATP1B1.
The approaches taken in this study indicate that relatively small amounts of literature data for drug transporters can be used to provide qualitative models of the key features involved in the ligand-protein interaction. By combining data from different experimental cell systems expressing the transporter, meta-models can be generated which comply with most criteria for robust pharmacophores. Namely these models have a sizeable difference between the null and total cost of the hypothesis and show a decrease in the average model correlation following scrambling of the molecule structures and the K m values. External testing validated the predictive ability of the models. These meta-pharmacophores are grossly similar to merged models of the multiple pharmacophores derived with individual datasets. This approach of merging individual models for the same transporter had previously been taken
18 with P-gp to show the concordance of five inhibitor pharmacophores and the tight clustering of hydrophobic features at the extremities and central hydrogen bonding features (Ekins et al., 2002) . The pharmacophores for OATP1B1 and Oatp1a1 ( Figure 3D-F) are distinctly different to those previously generated for P-gp in that the hydrophobic features are now centrally located pharmacophore features with the hydrogen bond acceptor features at the extremities.
In conclusion, we have shown for the first time that using limited data sets from different laboratories, cell types and species can be used successfully to derive robust computational pharmacophore models describing the key features for substrate interaction with rat Oatp1a1 and human OATP1B1 transporters. Our ultimate meta-pharmacophore approach combines data from different cell types and produces models which suggest a degree of similarity consistent with the biological data generated for each transporter to date ( Figure 3D-F) . We believe this meta-pharmacophore approach can be used with other transporters for which in vitro data are scattered across multiple experimental systems and species. Ultimately, this approach may aid in predicting potential drug-transporter or drugdrug interactions occurring at the key human transport proteins and overcome some of the variability due to the unique qualities of individual cell types and experimental systems used.
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